-
Anonymous users2024-02-10According to the pathological characteristics of cancer cells in lung cancer tissues, non-small cell lung cancer (NSCLC) accounts for about 85%, and small cell lung cancer (SCLC): accounts for about 15%.
For advanced non-small cell lung cancer, testing for ALK fusion genes or ALK fusion proteins is routinely recommended for all patients with adenocarcinoma or NSCLC components that contain adenocarcinoma components. ALK testing is also recommended for patients with small biopsy specimens or non-smoking squamous cell carcinoma. In 2009, Shaw et al. classified ALK rearrangement-positive lung cancer as a specific molecular subtype of non-small cell lung cancer.
ALK-fusion NSCLC is not only a change in the gene sequence, but also an important variant in ALK-fusion proteins, so such diseases are collectively referred to as "ALK-positive NSCLC". ALK-positive non-small cell lung cancer (NSCLC) is a type of lung cancer with well-defined driver genes. This type of non-small cell lung cancer is highly sensitive to ALK inhibitors, a new type of targeted drug.
The positive rate of ALK in non-small cell lung cancer in China is 3-11%, and the number of new cases is about 35,000 per year. For ALK-positive non-small cell lung cancer that is positive for gene mutations, targeting** has undoubtedly become a better choice for them**.
-
Anonymous users2024-02-09This must be checked out at the hospital.
-
Anonymous users2024-02-08Check it out.
-
Anonymous users2024-02-07According to the pathological characteristics of cancer cells in lung cancer tissues, non-small cell lung cancer (NSCLC) accounts for about 85%, and small cell lung cancer (SCLC): accounts for about 15%.
For advanced non-small cell lung cancer, testing for ALK fusion genes or ALK fusion proteins is routinely recommended for all patients with adenocarcinoma or NSCLC components that contain adenocarcinoma components.
ALK gene testing is also recommended for patients with small biopsy specimens or squamous cell carcinoma who do not smoke. In 2009, Shaw et al. classified ALK rearrangement-positive lung cancer as a specific molecular subtype of non-small cell lung cancer.
ALK-fusion NSCLC is not only a change in the gene sequence, but also an important variant in ALK-fusion proteins, so such diseases are collectively referred to as "ALK-positive NSCLC".
ALK-positive non-small cell lung cancer (NSCLC) is a type of lung cancer with well-defined driver genes. This type of non-small cell lung cancer is highly sensitive to ALK inhibitors, a new type of targeted drug.
The positive rate of ALK in non-small cell lung cancer in China is 3-11%, and the number of new cases is about 35,000 per year. For ALK-positive non-small cell lung cancer that is positive for gene mutations, targeting** has undoubtedly become a better choice for them**.
At present, the commonly used drugs are gefitinib and erlotinib, and the lung cancer guidelines formulated by the Ministry of Health recommend gefitinib and erlotinib as the first-line for patients with advanced non-small cell lung cancer**, and it is recommended for patients with mutations to detect EGFR gene mutations. In addition, there are drugs that target tumor angiogenesis, such as bevacizumab, endostatin, etc.
Surgery is the first choice for non-small cell lung cancer**, and if it is not operable, targeted treatment** or chemotherapy can be chosen. However, no matter what kind of work you do, you must first do a puncture of the lung lesions, and take some tissues for genetic testing and pathological examination. Only those who are positive for EGFR can be targeted**, and it is meaningless to use target** for negative ones, and chemotherapy can only be done. >>>More
Hello, non-small cell lung cancer patients should choose different comprehensive modes according to the type and stage of pathology, follow the evidence-based medical basis, and choose different comprehensive modes under the guidance of doctors**, and the common methods at present include surgery, chemotherapy, radiotherapy, molecular targeted drugs**, traditional Chinese medicine** and local intervention**. Common chemotherapy drugs are cisplatin, carboplatin, gemcitabine, pemetrexed, and paclitaxel. If the EGFR gene is mutated, targeted drugs such as erlotinib and gefitinib can be selected. >>>More
In fact, we don't need to panic, it is not contagious. Next, I will introduce you to small cell lung cancer. Lung cancer is a serious disease that can lead to death. >>>More
The specific chemotherapy depends on the condition.
and physical condition. >>>More